40 results
Keyword Dynastat Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Dynastat
parecoxib sodium, Pain, Postoperative
Date of authorisation: 22/03/2002, Revision: 32, Authorised, Last updated: 17/08/2022Dynastat Pathological Conditions … Dynastat … 0)88 781 6000 Dynastat Procedural steps taken and … -
List item
News: Public statement on Parecoxib Sodium (Dynastat/Rayzon/Xapit) on the risk of serious hypersensitivity and skin reactions
Last updated: 22/10/2002statement on Parecoxib Sodium (Dynastat/Rayzon/Xapit) on the risk of serious hypersensitivity … patients with parecoxib sodium (Dynastat/Rayzon/Xapit): This product is contraindicated … side effects with parecoxib (Dynastat/Rayzon/Xapit). If you experience Skin … -
List item
News: European Medicines Agency public statement on valdecoxib and parecoxib sodium. Cardiovascular risks in coronary artery bypass graft surgery and serious adverse skin reactions
Last updated: 15/12/2004stop taking Bextra/Valdyn or Dynastat/Rayzon and tell your doctor, pharmacist … Bextra/Valdyn (valdecoxib): EPAR Dynastat/Rayzon (parecoxib): EPAR Contact … Bextra/Valdyn) and PARECOXIB SODIUM (Dynastat/Rayzon) CARDIOVASCULAR RISKS IN … -
List item
Press release: European Medicines Agency statement on celecoxib
Last updated: 17/12/2004Bextra/Valdyn (valdecoxib): EPAR Dynastat/Rayzon (parecoxib): EPAR Onsenal … valdecoxib), [here] for Dynastat/Rayzon (parecoxib) and [here] for … -
List item
Press release: European Medicines Agency to review COX-2 inhibitors
Last updated: 22/10/2004Bextra/Valdyn (valdecoxib): EPAR Dynastat/Rayzon (parecoxib): EPAR Onsenal … valdecoxib), [here] for Dynastat/Rayzon (parecoxib) and [here] for … -
List item
Referral: Celecoxib
celecoxib, Article 31 referrals
Status: European Commission final decision, opinion/position date: 23/06/2005, EC decision date: 28/11/2005, Last updated: 06/12/2005celecoxib (Onsenal), parecoxib (Dynastat/Rayzon) and valdecoxib (Bextra/Valdyn … celecoxib (Onsenal), parecoxib (Dynastat/Rayzon) and valdecoxib (Bextra/Valdyn … -
List item
Referral: Lumiracoxib
lumiracoxib, Article 31 referrals
Status: European Commission final decision, opinion/position date: 23/06/2005, EC decision date: 28/11/2005, Last updated: 06/12/2005celecoxib (Onsenal), parecoxib (Dynastat/Rayzon) and valdecoxib (Bextra/Valdyn … celecoxib (Onsenal), parecoxib (Dynastat/Rayzon) and valdecoxib (Bextra/Valdyn … -
List item
Referral: Etoricoxib
etoricoxib, Article 31 referrals
Status: European Commission final decision, opinion/position date: 23/06/2005, EC decision date: 28/11/2005, Last updated: 06/12/2005celecoxib (Onsenal), parecoxib (Dynastat/Rayzon) and valdecoxib (Bextra/Valdyn … celecoxib (Onsenal), parecoxib (Dynastat/Rayzon) and valdecoxib (Bextra/Valdyn … -
List item
Human medicine European public assessment report (EPAR): Rayzon
parecoxib, Pain, Postoperative
Date of authorisation: 22/03/2002, Revision: 4, Withdrawn, Last updated: 23/08/2005containing parecoxib, i.e. Dynastat. As a consequence to this … -
List item
Human medicine European public assessment report (EPAR): Xapit
parecoxib, Pain, Postoperative
Date of authorisation: 22/03/2002, Withdrawn, Last updated: 23/08/2004containing parecoxib, i.e. Dynastat and Rayzon. On 02 March … -
List item
Human medicine European public assessment report (EPAR): Onsenal
Celecoxib, Adenomatous Polyposis Coli
Date of authorisation: 17/10/2003,
, Revision: 13, Withdrawn, Last updated: 06/04/2011
-
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 April 2022
European Medicines Agency, Amsterdam, the Netherlands, from 19/04/2022 to 22/04/2022, Last updated: 12/08/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 20-23 June 2022
European Medicines Agency, Amsterdam, the Netherlands, from 20/06/2022 to 23/06/2022, Last updated: 18/08/2022 -
List item
Download medicine data
Last updated: 02/12/2021 -
List item
Press release: European Medicines Agency concludes action on COX-2 inhibitors
Last updated: 27/06/2005 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 26-29 November 2012
European Medicines Agency, London, UK, from 26/11/2012 to 29/11/2012, Last updated: 26/11/2012 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 6-9 February 2017
European Medicines Agency, London, UK, from 06/02/2017 to 09/02/2017, Last updated: 13/03/2014 -
List item
Press release: European Medicines Agency statement following withdrawal of Vioxx (rofecoxib)
CHMP, Last updated: 06/10/2004Bextra/Valdyn (valdecoxib), here for Dynastat/Rayzon (parecoxib) and here for … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 3-6 November 2014
European Medicines Agency, London, UK, from 03/11/2014 to 06/11/2014, Last updated: 13/08/2013 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 23-26 November 2020
Virtual meeting, from 23/11/2020 to 26/11/2020, Last updated: 27/11/2020 -
List item
News: European Medicines Agency public statement on the suspension of the marketing authorisation for bextra (valdecoxib) in the European Union
Last updated: 27/10/2005celecoxib (Onsenal), parecoxib (Dynastat/Rayzon) and valdecoxib (Bextra/Valdyn … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 27-30 November 2017
European Medicines Agency, London, UK, from 27/11/2017 to 30/11/2017, Last updated: 27/11/2017 -
List item
Press release: European Medicines Agency: Committee for Medicinal Products for Human Use 18 – 21 April 2005
CHMP, Last updated: 21/04/2005parent compound parecoxib (Dynastat). The Committee discussed … -
List item
Press release: Committee for Proprietary Medicinal Products (CPMP): meeting of 13 to 15 November 2001
Last updated: 16/11/2001Xapit (parecoxib sodium), Dynastat (parecoxib sodium) and … -
List item
Public data from Article 57 database (updated)
Last updated: 22/09/2022